首次复治肺结核病结核分枝杆菌对利福平耐药性与rpoB基因RRDR突变的研究

doi:10.16150/j.1671-2870.2018.06.003

诊断学理论与实践 ›› 2018, Vol. 17 ›› Issue (06): 635-639.doi: 10.16150/j.1671-2870.2018.06.003

首次复治肺结核病结核分枝杆菌对利福平耐药性与rpoB基因RRDR突变的研究

程齐俭¹, 陈聆¹, 杜威², 柳亚慧², 杨华³, 肖和平³, 时国朝²

1.上海交通大学医学院附属瑞金医院北院呼吸内科, 上海201801;
2.上海交通大学医学院附属瑞金医院呼吸与危重病学科上海市重中之重临床重点学科上海交通大学医学院呼吸病研究所, 上海200025;
3.同济大学医学院肺科医院结核科, 上海200433

收稿日期:2018-11-07 出版日期:2018-12-25 发布日期:2018-12-25
通讯作者: 肖和平 E-mail: xiaoheping_sars@163.com;时国朝 E-mail: shi_guochao@vip.163.com
基金资助:
国家科技重大专项（2013ZX10003009）

Multicenter study on rpoB mutation in rifampicin-resistant Mycobacterium tuberculosis isolates of initial retreatment pulmonary tuberculosis

CHENG Qijian¹, CHEN Ling¹, DU Wei², LIU Yahui², YANG Hua³, XIAO Heping³, SHI Guochao²

1. Department of Pulmonary Disease, RuiJin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China;
2. Department of Pulmonary and Critical Care Medicine, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201801, China;
3. Department of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China

Received:2018-11-07 Online:2018-12-25 Published:2018-12-25

摘要/Abstract

摘要： 目的：研究分离自首次复治肺结核病患者的结核分枝杆菌（Mycobacterium tuberculosis, Mtb）临床菌株对利福平的耐药性, 及其与rpoB基因利福霉素耐药决定区（rifampicin resistance determining regions, RRDR）位点突变间的相关性。方法：收集2013年2月至2013年12月国内19家医院的首次复治肺结核患者的Mtb, 进行利福平药敏检测;使用PCR技术检测Mtb的rpoB基因RRDR位点突变。结果：来自全国12个省19家医院共141例患者的141株临床菌株获得药敏结果, 而RRDR位点测序分析显示首次复治结核患者中有53%（75/141）对利福平耐药。RRDR DNA测序共检测到72株Mtb存在rpoB耐药突变区突变, 其中71株的突变发生在RRDR, 主要突变位点分别为531位（42株）、526位（11株）和516位（10株）。有75株Mtb对利福平耐药, 其中70株（93.3%）检测到rpoB突变, 69株的突变发生在RRDR;除了2株L511P、H526N突变的Mtb对利福平敏感, 70株rpoB突变株均对利福平耐药。对于复治结核患者, 检测RRDR突变判断利福平耐药有较高的特异度。结论：首次复治肺结核病患者对利福平耐药率较高, Mtb耐利福平与rpoB基因RRDR突变密切相关, RRDR突变检测可以用于快速鉴定复治肺结核病患者的Mtb利福平耐药。

关键词: 结核分枝杆菌, 利福平, 耐药, rpoB

Abstract: Objective: To observe the association between mutation of rifampicin resistance determining regions (RRDR) of rpoB gene and rifampicin resistance in rifampicin-resistant Mycobacterium tuberculosis(Mtb) strains isolated from initial retreatment pulmonary tuberculosis. Methods: Mtb isolates from pulmonary tuberculosis patients who had previous treated were collected. Drug susceptibility was identified through BACTEC 960 and Roche medium; rpoB gene mutation was analyzed by polymerase chain reaction (PCR). Results: A total of 141 isolates from 141 patients in 19 hospitals from 12 provinces across the country were tested for drug sensitivity and analysis of RRDR loci sequencing. Point mutations were identified in 72 strains by sequencing and 71 were in RRDR. The main mutation sites included codon 531 (42 strains), 526 (11 strains) and 516 (10 strains). Seventy-five strains were resistant to rifampicin (RFP), of which 70 (93.3%) had rpoB mutation and 69 were in RRDR. Only two strains with RRDR mutation (L511P and H526N mutant Mtb) were sensitive to rifampicin, and 70 rpoB mutation strains were resistant to rifampicin. Conclusions: The rifampicin-resistance in Mtb isolates from initial retreatment pulmonary tuberculosis is associated with rpoB gene RRDR mutation. RRDR mutation detection can be used for rapid identification of rifampicin-resistant Mtb in retreated patients.

Key words: Mycobacterium tuberculosis, Rifampicin, Drug resistance, rpoB

中图分类号:

R378.91⁺1

程齐俭, 陈聆, 杜威, 柳亚慧, 杨华, 肖和平, 时国朝. 首次复治肺结核病结核分枝杆菌对利福平耐药性与rpoB基因RRDR突变的研究[J]. 诊断学理论与实践, 2018, 17(06): 635-639.

CHENG Qijian, CHEN Ling, DU Wei, LIU Yahui, YANG Hua, XIAO Heping, SHI Guochao. Multicenter study on rpoB mutation in rifampicin-resistant Mycobacterium tuberculosis isolates of initial retreatment pulmonary tuberculosis[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(06): 635-639.

参考文献

[1] World Health Organization. Global Tuberculosis Report[R/OL]. Geneva.(2017)[2018-12-01].https://www.scirp.org/reference/ReferencesPapers.aspx?ReferenceID=2240945.
[2] Rattan A, Kalia A, Ahmad N.Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives[J]. Emerg Infect Dis,1998,4(2):195-209.
[3] Long R.Drug-resistant tuberculosis[J]. CMAJ,2000,163(4):425-428.
[4] Ramaswamy S, Musser JM.Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update[J]. Tuber Lung Dis,1998,79(1):3-29.
[5] World Health Organization. Policy guidance on drug-susceptibility testing(DST) of second-line anti-tuberculosis drugs[R/OL]. Geneva, Switzerland,(2008)[2018-12-01].http://www.who.int/tb/publications/whohtmtb_2008_392/en/
[6] Lai C, Xu J, Tozawa Y, et al.Genetic and physiological characterization of rpoB mutations that activate antibiotic production in Streptomyces lividans[J]. Microbiology,2002,148(Pt 11):3365-3373.
[7] Prim RI, Schörner MA, Senna SG, et al.Molecular profiling of drug resistant isolates of Mycobacterium tuberculosis in the state of Santa Catarina, southern Brazil[J]. Mem Inst Oswaldo Cruz,2015,110(5):618-623.
[8] Thirumurugan R, Kathirvel M, Vallayyachari K, et al.Molecular analysis of rpoB gene mutations in rifampicin resistant Mycobacterium tuberculosis isolates by multiple allele specific polymerase chain reaction in Puducherry, South India[J]. J Infect Public Health,2015,8(6):619-625.
[9] Minh NN, Van Bac N, Son NT, et al.Molecular characteristics of rifampin- and isoniazid-resistant mycobacte-rium tuberculosis strains isolated in Vietnam[J]. J Clin Microbiol,2012,50(3):598-601.
[10] Dookie N, Sturm AW, Moodley P.Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa[J]. BMC Infect Dis,2016, 16(1):609.
[11] Chen L, Gan X, Li N, et al.rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China[J]. J Antimicrob Chemother,2010,65(6):1299-1301.
[12] Qazi O, Rahman H, Tahir Z, et al.Mutation pattern in rifampicin resistance determining region of gene in multidrug-resistant Mycobacterium tuberculosis isolates from Pakistan[J]. Int J Mycobacteriol,2014,3(3):173-177.
[13] Htike Min PK, Pitaksajjakul P, Tipkrua N, et al.Novel mutation detection IN rpoB OF rifampicin-resistant Mycobacterium tuberculosis using pyrosequencing[J]. Southeast Asian J Trop Med Public Health,2014,45(4):843-852.
[14] Torres MJ, Criado A, Gónzalez N, et al.Rifampin and isoniazid resistance associated mutations in Mycobacte-rium tuberculosis clinical isolates in Seville, Spain[J]. Int J Tuberc Lung Dis,2002,6(2),160-163.
[15] Spindola de Miranda S, Kritski A, Filliol I, et al. Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains isolated in Brazil and France[J]. Mem Inst Oswaldo Cruz,2001,96(2):247-250.
[16] Mikhailovich V, Lapa S, Gryadunov D, et al.Identification of rifampin-resistant Mycobacterium tuberculosis strains by hybridization, PCR, and ligase detection reaction on oligonucleotide microchips[J]. J Clin Microbiol,2001,39(7):2531-2540.
[17] Pozzi G, Meloni M, Iona E, et al.rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy[J]. J Clin Microbiol,1999,37(4):1197-1199.
[18] Bártfai Z, Somoskövi A, Ködmön C, et al.Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay[J]. Clin Microbiol,2001,39(10):3736-3739.
[19] Sajduda A, Brzostek A, Poplawska M, et al.Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland[J]. J Clin Microbiol,2004,42(6):2425-2431.
[20] Cooksey RC, Morlock GP, Glickman S, et al.Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City[J]. J Clin Microbiol,1997, 35(5):1281-1283.
[21] Williams DL, Waguespack C, Eisenach K, et al.Characterization of rifampin-resistance in pathogenic mycobacteria[J]. Antimicrob Agents Chemother,1994,38(10):2380-2386.
[22] Lee AS, Lim IH, Tang LL, et al.High frequency of mutations in the rpoB gene in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Singapore[J]. J Clin Microbiol,2005,43(4):2026-2027.
[23] Sheng J, Li J, Sheng G, et al.Characterization of rpoB mutations associated with rifampin resistance in Mycobacterium tuberculosis from eastern China[J]. J Appl Microbiol,2008,105(3):904-911.
[24] 胡族琼, 刘燕文, 周文, 等. 结核分枝杆菌rpoB基因突变特征与利福平耐药水平关系的研究[J]. 中国人兽共患病学报,2016,32(1):39-44.

首次复治肺结核病结核分枝杆菌对利福平耐药性与rpoB基因RRDR突变的研究

Multicenter study on rpoB mutation in rifampicin-resistant Mycobacterium tuberculosis isolates of initial retreatment pulmonary tuberculosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436.
[2]	胡静静, 吕海伟, 荀静娜, 沈银忠, 刘莉, 卢洪洲. 2012年至2021年上海市艾滋病合并分枝杆菌感染患者的菌种分布特征[J]. 诊断学理论与实践, 2022, 21(04): 450-455.
[3]	李丽, 朱咏臻, 周敏, 钱嘉, 方丽莉. 2017年至2021年上海嘉定区某医院多重耐药菌分析[J]. 诊断学理论与实践, 2022, 21(01): 62-67.
[4]	陈华, 刘锦燕, 李文静, 赵珺涛, 项明洁. 新型咪唑类药物2-咪唑-2,4-戊二烯酮19和44对白念珠菌抗菌效果和作用机制初步研究[J]. 诊断学理论与实践, 2021, 20(04): 356-361.
[5]	王院霞, 姚锂凤, 郑巧平, 陈旭. 9株分离自住院患者的CA-MRSA基因型菌株的分子特征及耐药性研究[J]. 诊断学理论与实践, 2021, 20(01): 66-70.
[6]	王安琪, 王士礼, 郎军添, 向明亮. 224例慢性化脓性中耳炎患者耳分泌物培养结果及多重耐药菌感染分析[J]. 诊断学理论与实践, 2021, 20(01): 88-92.
[7]	孔娜娜, 张培燕, 杨德平, 金慧敏, 郑江花. 上海周浦地区2016年至2020年尿路感染者病原体分布情况及耐药性检测[J]. 诊断学理论与实践, 2021, 20(01): 93-97.
[8]	刁文晶, 皇甫昱婵, 朱威南, 刘婧娴, 刘瑛, 沈立松. 耐碳青霉烯类大肠埃希菌临床分离情况及碳青霉烯酶基因研究[J]. 诊断学理论与实践, 2019, 18(06): 655-661.
[9]	顾勤, 王泰蓉, 陈荔萍, 吴舒窈, 沈祎. 社区老年女性糖尿病患者尿路感染常见病原菌调查[J]. 诊断学理论与实践, 2019, 18(05): 538-542.
[10]	蒋晓飞, 周迎. 碳青霉烯耐药肺炎克雷伯菌的耐药与传播机制研究进展及对策[J]. 诊断学理论与实践, 2018, 17(06): 623-629.
[11]	何梅芳, 刘健红, 陈春华, 申红玉. 全血γ-干扰素释放试验与ELISA检测结核分枝杆菌抗体在痰菌阴性肺结核辅助诊断中的比较应用[J]. 诊断学理论与实践, 2018, 17(05): 586-589.
[12]	康健捷, 杨红军, 邓兵梅, 邵腾飞. 利福平致药源性流感样综合征一例临床分析[J]. 诊断学理论与实践, 2018, 17(04): 460-461.
[13]	沈晓红, 陈慧芬, 张军, 叶剑波, 张贤华. 2014年至2017年上海地区新生儿血流感染病原菌分布及其耐药性分析[J]. 诊断学理论与实践, 2018, 17(03): 266-271.
[14]	曹雪萍, 张贤华, 陈慧芬, 沈平华. 2015年至2017年上海地区无乳链球菌临床感染情况及耐药性分析[J]. 诊断学理论与实践, 2018, 17(03): 308-310.
[15]	刘锦燕, 王影, 李文静, 赵悦, 孟玲宁, 朱巍巍, 史册, 项明洁. 体外氟康唑诱导光滑念珠菌和近平滑念珠菌耐药及相关机制研究[J]. 诊断学理论与实践, 2017, 16(05): 510-515.